Mabpharm Limited
2181.HK
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.12B
Close$
Share Statistics
| Market cap | $2.12 Billion |
|---|---|
| Enterprise Value | $2.39 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $0.01 |
| Beta | 0.61 |
| Outstanding Shares | 4,124,080,000 |
Return
| Return on Equity | 29.54% |
|---|---|
| Return on Assets | 4.90% |
| Return on Invested Capital | 1.92% |
Valuation & Multiples
| P/E Ratio | 21.39 |
|---|---|
| PEG | 2.17 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 2.02 |
| Enterprise Value to EBIT | 187.86 |
| Enterprise Value to Net Income | 41 |
| Total Debt to Enterprise | 0.15 |
| Debt to Equity | 1.88 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 28, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
March 31, 2027
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Mabpharm Limited
394 employees
CEO: Hao Wang Mabpharm Limited is a Chinese biopharmaceutical firm dedicated to the research, development, and manufacturing of innovative and biosimilar medications. Its therapeutic focus areas include allergic conditions, various cancers, and autoim...